Sanofi (NASDAQ:SNY) Shares Purchased by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 4.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,689 shares of the company's stock after buying an additional 5,532 shares during the period. Mercer Global Advisors Inc. ADV's holdings in Sanofi were worth $5,966,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of the company. Arkadios Wealth Advisors lifted its stake in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after purchasing an additional 751 shares during the last quarter. Kentucky Trust Co purchased a new stake in shares of Sanofi in the fourth quarter worth about $436,000. Park Avenue Securities LLC raised its position in Sanofi by 14.3% during the fourth quarter. Park Avenue Securities LLC now owns 68,982 shares of the company's stock valued at $3,327,000 after acquiring an additional 8,615 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Sanofi by 18.1% in the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock valued at $31,965,000 after acquiring an additional 101,726 shares during the period. Finally, Sound Income Strategies LLC boosted its position in Sanofi by 156,520.9% in the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company's stock worth $3,248,000 after purchasing an additional 67,304 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on SNY shares. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Sanofi has a consensus rating of "Buy" and a consensus target price of $63.33.

Sanofi Price Performance

Shares of NASDAQ:SNY traded down $0.88 during midday trading on Wednesday, hitting $52.27. The company had a trading volume of 2,128,719 shares, compared to its average volume of 2,359,759. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The business's 50-day simple moving average is $54.46 and its 200-day simple moving average is $52.04. The stock has a market cap of $132.05 billion, a price-to-earnings ratio of 20.99, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period last year, the business earned $1.78 earnings per share. Sanofi's revenue was down 11.0% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.